Pneumonitis in combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma

被引:1
作者
Yu, Nathan Y. [1 ]
Deftos, Michael [2 ]
Wang, Clifford C. [3 ]
机构
[1] Santa Clara Valley Med Ctr, Radiat Oncol, San Jose, CA 95128 USA
[2] Santa Clara Valley Med Ctr, Pathol, San Jose, CA 95128 USA
[3] Santa Clara Valley Med Ctr, Internal Med, San Jose, CA 95128 USA
来源
CUREUS | 2018年 / 10卷 / 12期
关键词
immunotherapy; pneumonitis; radiation therapy; nivolumab; renal cell carcinoma;
D O I
10.7759/cureus.3748
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-programed cell death-1 (Anti-PD-1) is a promising immunotherapy for advanced cancers. Autoimmune pneumonitis is a rare but potentially serious toxicity induced by anti-PD-1 immunotherapy. We report a case of therapy-induced pneumonitis in the setting of combined nivolumab, anti-PD-1 immunotherapy, and radiation therapy for metastatic renal cell carcinoma (RCC).
引用
收藏
页数:7
相关论文
共 16 条
[1]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[2]   The PD-1 pathway in tolerance and autoimmunity [J].
Francisco, Loise M. ;
Sage, Peter T. ;
Sharpe, Arlene H. .
IMMUNOLOGICAL REVIEWS, 2010, 236 :219-242
[3]   The promising role of nivolumab in renal cell cancers [J].
Gupta, Kanika ;
Tiu, Dorenett Yu ;
Tiu, John ;
Aragon-Ching, Jeanny B. .
CANCER BIOLOGY & THERAPY, 2016, 17 (02) :123-124
[4]  
Hiniker SM, 2012, NEW ENGL J MED, V366, P2035, DOI 10.1056/NEJMc1203984
[5]   Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade [J].
Iwai, Y ;
Ishida, M ;
Tanaka, Y ;
Okazaki, T ;
Honjo, T ;
Minato, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) :12293-12297
[6]   Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials [J].
Larkin, James ;
Lao, Christopher D. ;
Urba, Walter J. ;
McDermott, David F. ;
Horak, Christine ;
Jiang, Joel ;
Wolchok, Jedd D. .
JAMA ONCOLOGY, 2015, 1 (04) :433-440
[7]   Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab [J].
McDermott, David F. ;
Drake, Charles G. ;
Sznol, Mario ;
Choueiri, Toni K. ;
Powderly, John D. ;
Smith, David C. ;
Brahmer, Julie R. ;
Carvajal, Richard D. ;
Hammers, Hans J. ;
Puzanov, Igor ;
Hodi, F. Stephen ;
Kluger, Harriet M. ;
Topalian, Suzanne L. ;
Pardoll, Drew M. ;
Wigginton, Jon M. ;
Kollia, Georgia D. ;
Gupta, Ashok ;
McDonald, Dan ;
Sankar, Vindira ;
Sosman, Jeffrey A. ;
Atkins, Michael B. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2013-U42
[8]   Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].
Motzer, R. J. ;
Escudier, B. ;
McDermott, D. F. ;
George, S. ;
Hammers, H. J. ;
Srinivas, S. ;
Tykodi, S. S. ;
Sosman, J. A. ;
Procopio, G. ;
Plimack, E. R. ;
Castellano, D. ;
Choueiri, T. K. ;
Gurney, H. ;
Donskov, F. ;
Bono, P. ;
Wagstaff, J. ;
Gauler, T. C. ;
Ueda, T. ;
Tomita, Y. ;
Schutz, F. A. ;
Kollmannsberger, C. ;
Larkin, J. ;
Ravaud, A. ;
Simon, J. S. ;
Xu, L-A ;
Waxman, I. M. ;
Sharma, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813
[9]   Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis [J].
Nishino, Mizuki ;
Giobbie-Hurder, Anita ;
Hatabu, Hiroto ;
Ramaiya, Nikhil H. ;
Hodi, Stephen .
JAMA ONCOLOGY, 2016, 2 (12) :1607-1616
[10]   Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy [J].
Nishino, Mizuki ;
Sholl, Lynette M. ;
Hodi, F. Stephen .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) :288-290